Supplementary Table 4. Injection-site adverse experiences prompted for on the Vaccination Report Card.

	Concomitant administration (Group A)[a]	Non-concomitant administration (Group B)[a]	Difference in % between Group A and Group B' (95% CI)	p-value
A. 9vHPV vaccine injection site (reported days 1 to 5 post-dose 1)				
Number of subjects contributing to the analysis:	524	527[b]		
Erythema	43 (8.2)	30 (5.7)	2.5 (-0.6, 5.7)	0.109
Pain	310 (59.2)	319 (60.5)	-1.4 (-7.3, 4.6)	0.650
Swelling	68 (13.0)	43 (8.2)	4.8 (1.1, 8.6)	0.011
B. Tdap-IPV vaccine injection site (reported days 1 to 5 post-vaccination)				
Number of subjects contributing to the analysis:	525	520[c]		
Erythema	141 (26.9)	113 (21.7)	5.1 (-0.1, 10.3)	0.054
Pain	454 (86.5)	435 (83.7)	2.8 (-1.5, 7.2)	0.201
Swelling	207 (39.4)	163 (31.3)	8.1 (2.3, 13.8)	0.006

[a]Group A (concomitant administration) received a 0.5 mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5 mL dose of Tdap-IPV vaccine on day 1; Group B (non-concomitant administration) received 9vHPV vaccine as above and Tdap-IPV vaccine at month 1.

[b]One subject who was randomized into the Non-concomitant Group received 9vHPV vaccine at day 1 but did not did not receive Tdap-IPV at Month 1 and is excluded from this table.

[c]Of the 528 subjects randomized to Group B, eight did not receive Tdap-IPV vaccine at month 1 and are excluded from this table.